Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes

Shingo Morimitsu, Hidetaka Hamasaki


Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is a cornerstone for the management of obesity and type 2 diabetes. GLP-1RAs improve the glycemic control by suppressing glucagon secretion and stimulating insulin secretion in patients with type 2 diabetes. Here, we report the case of a patient with type 2 diabetes with postprandial hyperglucagonemia who was successfully treated by the administration of once-weekly dulaglutide. A 67-year-old, non-obese woman was admitted to our hospital for preoperative glycemic control. Her glycemic control significantly improved after the administration of dulaglutide. Both fasting and postprandial plasma glucagon levels were effectively suppressed by dulaglutide, which ameliorated hyperglycemia. Thus, to achieve an optimal glycemic control, clinicians should consider suppressing glucagon secretion in addition to improving insulin secretion and sensitivity.

J Endocrinol Metab. 2018;8(1):6-9


Type 2 diabetes; Glucagon-like peptide-1 receptor agonist; Glucagon

Full Text: HTML PDF

Browse  Journals  


Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics






Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.